C. Michael Neuwelt

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2009 · 1.4K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +13

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Genome-Wide Screen for Systemic Lupus Erythematosus Susceptibility Genes in Multiplex Families

Francisco P. Quismorio, Lin Li, Oh Joon Kwon et al. · Human Molecular Genetics · 1999 · 313 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Michelle Petri, Daniel J. Wallace, Alberto Spindler et al. · Arthritis & Rheumatism · 2013 · 240 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 236 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17